EGFR and lung adenocarcinoma: This is exemplified by the development of resistance to EGFR tyrosine kinase inhibitor (TKI), through emergence of a secondary T790M EGFR mutation in non-small-cell lung carcinoma (NSCLC) [3], which occurs in 50% of the patients with lung adenocarcinoma [4].